The Opportunity

GROW Group PLC (“the Company” or “GROW^®”) is a biopharmaceutical company that was launched in 2017 by Co-Founders Ben Langley and Dr. Ian Atkinson, who believed that the key to unlocking the medical potential of cannabis lay in the tools needed to deliver precision and quality compounds through biotechnological innovation. In a short timeframe, GROW^® has already become the leading UK supplier by revenue (>£1.5m per month) and patients (>10k monthly patients) providing prescribed cannabinoid medicine and is on track to be a European leader in 2024 and is already in five markets across two continents. GROW^® seeks to accelerate towards its goal of being the world’s leading supplier of medical cannabis by patient numbers by 2025.

GROW^® operates in both a vertically integrated and partner model to ensure the optimal, broadest supply of truly differentiated cannabis medicines to drive the best outcomes for patients. It has a unique model in that it exclusively distributes medical cannabis products for the top tier manufacturers, as well as having its own in-house product and GROW^® brand. As the UK’s largest importer and distributor of cannabis medicines, it clearly has benefited from its advantage in a market that is developing exponentially, following a growth trajectory that is closely tracking more mature European markets’ development.

GROW^®'s UK business has been profitable for two years.  It is now approaching 100 products on offer and aims to be the ‘Amazon of UK medicinal cannabis’.

GROW^® is also unique in that it is developing cost effective and innovative extraction, precision dose control and more effective delivery technologies. These technologies are patentable and GROW^® actively protects its innovations. It has three patents, one issued, one full submission, one provisional and two in the R&D pipeline.

GROW^® aims to IPO in 2025 and is seeking up to £5m of pre-IPO funding to accelerate growth and take advantage of various opportunities to increase the value of the Company prior to the IPO, including constructing a new processing/distribution hub, establishing German and Australian distribution facilities, further investment in branding/marketing, technology enhancements and working capital.